Enhancement of transdermal drug delivery via synergistic action of chemicals

Biochimica et Biophysica Acta - Biomembranes

Volumn 1788, Issue 11, 2009, Pages 2362-2373

  Karande, Pankaj ^a   Mitragotri, Samir ^b  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^b University of California   (United States)

Author keywords

Chemical; Enhancer; High throughput; Synergy; Transdermal

Indexed keywords

ACICLOVIR; ALCOHOL DERIVATIVE; AMIDE; AMINE; ANTINEOPLASTIC AGENT; CAFFEINE; CLONAZEPAM; DIAZEPAM; DICLOFENAC; DRUG VEHICLE; ESSENTIAL OIL; ESTER DERIVATIVE; ESTRADIOL; FATTY ACID; HYDROCARBON; LIPID; LIPOSOME; LORAZEPAM; MEFENAMIC ACID; OLIGOSACCHARIDE; PROPRANOLOL; PROPYLENE GLYCOL; SQUALENE; SULFOXIDE; SURFACTANT; TERPENE DERIVATIVE; TERPENOID DERIVATIVE; TIMOLOL MALEATE; UNINDEXED DRUG; ZIDOVUDINE;

AQUEOUS SOLUTION; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; DIFFUSION; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; HUMAN; HYDROPHILICITY; LIPID BILAYER; LIPOPHILICITY; MICROEMULSION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SKIN IRRITATION; SKIN PERMEABILITY; SKIN STRUCTURE; SKIN SURFACE; STATISTICAL MODEL; STRATUM CORNEUM; THERMODYNAMICS; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; EXCIPIENTS; HUMANS; SKIN; SKIN ABSORPTION;

EID: 71149118210     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2009.08.015     Document Type: Review

References (225)

1. Chen H., and Langer R. Oral particulate delivery: status and future trends. Adv. Drug Deliv. Rev. 34 2-3 (1998) 339-350
2. Nir Y., et al. Fear of injections in young adults: prevalence and associations. Am. J. Trop. Med. Hyg. 68 3 (2003) 341-344
3. Breau L.M., et al. Facial expression of children receiving immunizations: a principal components analysis of the child facial coding system. Clin. J. Pain 17 2 (2001) 178-186
4. Kane A., et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull. W.H.O. 77 10 (1999) 801-807
5. Miller M.A., and Pisani E. The cost of unsafe injections. Bull. W.H.O. 77 10 (1999) 808-811
6. Drachman D. Novel drug delivery systems-opportunities and caveats. Neurobiol. Aging 10 5 (1989) 632-633
7. Langer R. Novel drug delivery systems. Chem. Br. 26 3 (1990) 232
8. Vanbrunt J. Novel drug delivery systems. Biotechnology 7 2 (1989) 127-130
9. Thomas B.J., and Finnin B.C. The transdermal revolution. Drug Discov. Today 9 16 (2004) 697-703
10. Prausnitz M.R. Transdermal delivery of macromolecules: recent advances by modification of skin's barrier properties, Therapeutic Protein and Peptide Formulation and Delivery. ACS Symposium Series (675) (1997) 124-153
11. Barry B.W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur. J. Pharm. Sci. 14 2 (2001) 101-114
12. Pillai O., et al. Noninvasive transdermal delivery of peptides and proteins. Drugs Future 26 8 (2001) 779-791
13. Prausnitz M.R., Mitragotri S., and Langer R. Current status and future potential of transdermal drug delivery. Nat. Rev. Drug Discov. 3 2 (2004) 115-124
14. Guy R.H. Current status and future prospects of transdermal drug delivery. Pharm. Res. 13 12 (1996) 1765-1769
15. Bouwstra J.A. The skin, a well organized membrane. Colloids and Surfaces. A, Physicochem. Eng. Aspects 123 (1997) 403-413
16. Bos J.D., and Meinardi M.H.M. The 500 dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 9 3 (2000) 165-169
17. Mikszta J.A., et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat. Med. 8 4 (2002) 415-419
18. Matriano J.A., et al. Macroflux (R) microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. 19 1 (2002) 63-70
19. Verbaan F.J., et al. Improved piercing of microneedle arrays in dermatomed human skin by an impact insertion method. J. Control. Release 128 1 (2008) 80-88
20. McAllister D.V., Allen M.G., and Prausnitz M.R. Microfabricated microneedles for gene and drug delivery. Annu. Rev. Biomed. Eng. 2 (2000) 289-313
21. Prausnitz M.R. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 56 5 (2004) 581-587
22. Sivamani R.K., Liepmann D., and Malbach H.I. Microneedles and transdermal applications. Expert Opin. Drug Deliv. 4 1 (2007) 19-25
23. Arora A., et al. Needle-free delivery of macromolecules across the skin by nanoliter-volume pulsed microjets. Proc. Natl. Acad. Sci. U. S. A. 104 11 (2007) 4255-4260
24. Baxter J., and Mitragotri S. Needle-free liquid jet injections: mechanisms and applications. Expert Rev. Med. Devices 3 5 (2006) 565-574
25. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat. Rev. Drug Discov. 5 7 (2006) 543-548
26. Kendall M., Mitchell T., and Wrighton-Smith P. Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications. J. Biomech. 37 11 (2004) 1733-1741
27. Tezel A., et al. Topical delivery of anti-sense oligonucleotides using low-frequency sonophoresis. Pharm. Res. 21 12 (2004) 2219-2225
28. Tezel A., and Mitragotri S. Interactions of inertial cavitation bubbles with stratum corneum lipid bilayers during low-frequency sonophoresis. Biophys. J. 85 6 (2003) 3502-3512
29. Ng K.Y. Enhancing transdermal drug transport with low-frequency ultrasound. Drug Discov. Today 9 21 (2004) 913
30. Smith N.B. Perspectives on transdermal ultrasound mediated drug delivery. Int. J. Nanomed. 2 4 (2007) 585-594
31. Mitragotri S., and Kost J. Low-frequency sonophoresis-a review. Adv. Drug Deliv. Rev. 56 5 (2004) 589-601
32. Ogura M., Paliwal S., and Mitragotri S. Low-frequency sonophoresis: current status and future prospects. Adv. Drug Deliv. Rev. 60 10 (2008) 1218-1223
33. Fan Q., Sirkar K.K., and Michniak B. Iontophoretic transdermal drug delivery system using a conducting polymeric membrane. J. Membr. Sci. 321 2 (2008) 240-249
34. Kogure K., et al. Transdermal delivery of insulin-encapsulated liposomes via iontophoresis. Yakugaku Zasshi (J. Pharm. Soc. Japan) 128 (2008) 81-82
35. Lerner E.N., Van Zanten E.H., and Stewart G.R. Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration. J. Drug Target. 12 5 (2004) 273-280
36. Denet A.R., Vanbever R., and Preat V. Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev. 56 5 (2004) 659-674
37. Pliquett U. Mechanistic studies of molecular transdermal transport due to skin electroporation. Adv. Drug Deliv. Rev. 35 1 (1999) 41-60
38. Delgado-Charro M.B., and Guy R.H. Transdermal iontophoresis for controlled drug delivery and non-invasive monitoring. STP Pharm. Sci. 11 6 (2001) 403-414
39. Panchagnula R., et al. Transdermal iontophoresis revisited. Curr. Opin. Chem. Biol. 4 4 (2000) 468-473
40. Lee W.R., et al. Lasers and microdermabrasion enhance and control topical delivery of vitamin C. J. Invest. Dermatol. 121 5 (2003) 1118-1125
41. Svedman P., Lundin S., and Svedman C. Administration of antidiuretic peptide (ddavp) by way of suction deepithelialized skin. Lancet 337 8756 (1991) 1506-1509
42. Svedman P., et al. Passive drug diffusion via standardized skin mini-erosion; methodological aspects and clinical findings with new device. Pharm. Res. 13 9 (1996) 1354-1359
43. Baron E.D., et al. Laser-assisted penetration of topical anesthetic in adults. Arch. Dermatol. 139 10 (2003) 1288-1290
44. Veremis-Ley M., et al. Laser-assisted penetration of allergens for patch testing. Dermatitis 17 1 (2006) 15-22
45. Lee S., et al. Photomechanical transcutaneous delivery of macromolecules. J. Invest. Dermatol. 111 6 (1998) 925-929
46. Lee S., et al. Topical drug delivery in humans with a single photomechanical wave. Pharm. Res. 16 11 (1999) 1717-1721
47. Doukas A.G., and Kollias N. Transdermal drug delivery with a pressure wave. Adv. Drug Deliv. Rev. 56 5 (2004) 559-579
48. Sintov A.C., et al. Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs. J. Control. Release 89 2 (2003) 311-320
49. Murthy S.N. Magnetophoresis: an approach to enhance transdermal drug diffusion. Pharmazie 54 5 (1999) 377-379
50. Murthy S.N., and Hiremath S.R.R. Magnetophoresis: a novel approach in transdermal drug permeation enhancement. J. Control. Release 72 1-3 (2001) 240-243
51. Blank I.H., Scheuple R.J., and Macfarla D.J. Mechanism of percutaneous absorption .3. Effect of temperature on transport of non-electrolytes across skin. J. Invest. Dermatol. 49 6 (1967) 582
52. Clarys P., et al. In vitro percutaneous penetration through hairless rat skin: influence of temperature, vehicle and penetration enhancers. Eur. J. Pharm. Biopharm. 46 3 (1998) 279-283
53. Akomeah F., et al. Effect of heat on the percutaneous absorption and skin retention of three model penetrants. Eur. J. Pharm. Sci. 21 2-3 (2004) 337-345
54. Klemsdal T.O., Gjesdal K., and Bredesen J.E. Heating and cooling of the nitroglycerin patch application area modify the plasma-level of nitroglycerin. Eur. J. Clin. Pharmacol. 43 6 (1992) 625-628
55. Shomaker T.S., Zhang J., and Ashburn M.A. A pilot study assessing the impact of heat on the transdermal delivery of testosterone. J. Clin. Pharmacol. 41 6 (2001) 677-682
56. Karande P., et al. Design principles of chemical penetration enhancers for transdermal drug delivery. Proc. Natl. Acad. Sci. U. S. A. 102 13 (2005) 4688-4693
57. Barry B.W. Breaching the skin's barrier to drugs. Nat. Biotechnol. 22 2 (2004) 165-167
58. Kim Y.C., et al. Synergistic enhancement of skin permeability by N-lauroylsarcosine and ethanol. Int. J. Pharm. 352 1-2 (2008) 129-138
59. Barry B.W. Lipid-protein-partitioning theory of skin penetration enhancement. J. Control. Release 15 3 (1991) 237-248
60. Buyuktimkin N., Buyuktimkin S., and Rytting J.H. Chemical means of transdermal drug permeation enhancement. In: Ghosh T.K., Pfister W.R., and Yum S. (Eds). Transdermal and Topical Drug Delivery Systems (1997), Informa Health Care
61. Roberts M.S., and Walker M. Water: the most natural penetration enhancer. In: Walters K., and Hadgraft J. (Eds). Pharmaceutical Skin Penetration Enhancement (1993), Marcel Dekker, New York 1-30
62. Hori M., et al. Enhancement of propranolol hydrochloride and diazepam skin absorption in vitro-effect of enhancer lipophilicity. J. Pharm. Sci. 80 1 (1991) 32-35
63. Rahman M.S., et al. Investigation of the in vitro interaction of various vehicles with hairless mouse skin. J. Soc. Cosmet. Chem. 43 5 (1992) 251-258
64. Takahashi K., et al. Invitro transport of sodium diclofenac across rat abdominal skin - effect of selection of oleaginous component and the addition of alcohols to the vehicle. Chem. Pharm. Bull. 39 1 (1991) 154-158
65. Loth H. Vehicular influence on transdermal drug penetration. Int. J. Pharm. 68 1-3 (1991) 1-10
66. Williams A.C., and Barry B.W. Skin absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 9 3-4 (1992) 305-353
67. Ghosh T.K., and Banga A.K. Methods of enhancement of transdermal drug delivery: part IIB, chemical permeation enhancers. Pharm. Technol. 17 5 (1993) 68-76
68. Ghosh T.K., and Banga A.K. Methods of enhancement of transdermal drug delivery: part IIA, chemical permeation enhancers. Pharm. Technol. 17 4 (1993) 62-80
69. Yum S., et al. Permeation enhancement with ethanol: mechanism of action through skin. In: Hsieh D.S. (Ed). Drug Permeation Enhancement: Theory and Applications (1994), Marcel Dekker, New York 143-170
70. Komata Y., Kaneko A., and Fujie T. In vitro percutaneous-absorption of thiamine disulfide through rat skin from a mixture of propylene-glycol and fatty-acid or its analog. Chem. Pharm. Bull. 40 8 (1992) 2173-2176
71. Komata Y., Kaneko A., and Fujie T. Effect of fatty-acid on the accumulation of thiamine disulfide in rat skin. Biol. Pharm. Bull. 17 5 (1994) 705-708
72. Lo W., et al. Dynamic investigation of the enhancing mechanism of the oleic acid-induced transdermal delivery using multiphoton generalized polarization microscopy. Biophys. J. 88 1 (2005) 335A
73. Meshulam Y., et al. Transdermal penetration of physostigmine. Effects of oleic acid enhancer. Drug Dev. Res. 28 4 (1993) 510-515
74. Yu B., et al. Visualization of oleic acid-induced transdermal diffusion pathways using two-photon fluorescence microscopy. J. Invest. Dermatol. 120 3 (2003) 448-455
75. Michniak B.B., Chapman J.M., and Seyda K.L. Facilitated transport of 2 model steroids by esters and amides of clofibric acid. J. Pharm. Sci. 82 2 (1993) 214-219
76. Michniak B.B., et al. Azone analogs as penetration enhancers-effect of different vehicles on hydrocortisone acetate skin permeation and retention. J. Control. Release 32 2 (1994) 147-154
77. Godwin D.A., et al. Synthesis and investigation of urea compounds as transdermal penetration enhancers. Int. J. Pharm. 167 1-2 (1998) 165-175
78. Hrabalek A., et al. Urea derivatives as transdermal penetration enhancers. Chemicke Listy 91 9 (1997) 682-683
79. Mollgaard B. Synergistic effects in percutaneous enhancement. In: Walters K., and Hadgraft J. (Eds). Pharmaceutical Skin Penetration Enhancement (1993), Marcell Dekker, New York, Hong Kong, Basel 229-242
80. Karande P., et al. Synergistic effects of chemical enhancers on skin permeability: a case study of sodium lauroylsarcosinate and sorbitan monolaurate. Eur. J. Pharm. Sci. 31 1 (2007) 1-7
81. Karande P., Jain A., and Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening. Nat. Biotechnol. 22 2 (2004) 192-197
82. French E.J., Pouton C.W., and Walters K.A. Mechanisms and prediction of nonionic surfactant effects on skin permeability. In: Walters K., and Hadgraft J. (Eds). Pharmaceutical Skin Penetration Enhancement (1993), Marcel Dekker, New York 113-143
83. Black J. Interaction between anionic surfactants and skin. In: Walters K., and Hadgraft J. (Eds). Pharmaceutical Skin Penetration Enhancement (1993), Marcel Dekker, New York 145-173
84. Aqil M., et al. Status of terpenes as skin penetration enhancers. Drug Discov. Today 12 23-24 (2007) 1061-1067
85. Bauerova K., Matusova D., and Kassai Z. Chemical enhancers for transdermal drug transport. Eur. J. Drug Metab. Pharmacokinet. 26 1-2 (2001) 85-94
86. Sapra B., Jain S., and Tiwary A.K. Percutaneous permeation enhancement by terpenes: mechanistic view. AAPS J. 10 1 (2008) 120-132
87. Cosco D., et al. Colloidal carriers for the enhanced delivery through the skin. Expert Opin. Drug Deliv. 5 7 (2008) 737-755
88. Dubey V., et al. Vesicles as tools for the modulation of skin permeability. Expert Opin. Drug Deliv. 4 6 (2007) 579-593
89. Albers E., and Muller B.W. Cyclodextrin derivatives in pharmaceutics. Crit. Rev. Ther. Drug Carrier Syst. 12 4 (1995) 311-337
90. Cal K., and Centkowska K. Use of cyclodextrins in topical formulations: practical aspects. Eur. J. Pharm. Biopharm. 68 3 (2008) 467-478
91. Loftsson T., and Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int. J. Pharm. 225 1-2 (2001) 15-30
92. Loftsson T., and Olafsson J.H. Cyclodextrins: new drug delivery systems in dermatology. Int. J. Dermatol. 37 4 (1998) 241-246
93. Loftsson T., et al. Effects of cyclodextrins on drug delivery through biological membranes. J. Pharm. Sci. 96 10 (2007) 2532-2546
94. Matsuda H., and Arima H. Cyclodextrins in transdermal and rectal delivery. Adv. Drug Deliv. Rev. 36 1 (1999) 81-99
95. Masson M., et al. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J. Control. Release 59 1 (1999) 107-118
96. De Paula D., et al. Enhancing effect of modified beta-cyclodextrins on in vitro skin permeation of estradiol. Brazilian J. Pharm. Sci. 43 1 (2007) 111-120
97. Jug M., et al. Influence of cyclodextrin complexation on piroxicam gel formulations. Acta Pharm. 55 (2005) 223-236
98. Lopes P.S., et al. Evaluation of in vitro percutaneous enhancement effect of papain and pequi oil on diclofenac sodium permeation through human skin. Brazilian J. Pharm. Sci. 44 2 (2008) 225-231
99. Geinoz S., et al. Quantitative structure-permeation relationships (QSPeRs) to predict skin permeation: a critical evaluation. Pharm. Res. 21 1 (2001) 83-92
100. Kanikkannan N., et al. Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery. Curr. Med. Chem. 7 6 (2000) 593-608
101. Ghafourian T., et al. The effect of penetration enhancers on drug delivery through skin: a QSAR study. J. Control. Release 99 1 (2004) 113-125
102. Pugh W.J., Degim I.T., and Hadgraft J. Epidermal permeability-penetrant structure relationships: 4, QSAR of permeant diffusion across human stratum corneum in terms of molecular weight, H-bonding and electronic charge. Int. J. Pharm. 197 1-2 (2000) 203-211
103. Santos-Filho O.A., Hopfinger A.J., and Zheng T. Characterization of skin penetration processes of organic molecules using molecular similarity and QSAR analysis. Mol. Pharm. 1 6 (2004) 466-476
104. Prausnitz M.R., and Langer R. Transdermal drug delivery. Nat. Biotechnol. 26 11 (2008) 1261-1268
105. Karande P., Jain A., and Mitragotri S. Insights into synergistic interactions in binary mixtures of chemical permeation enhancers for transdermal drug delivery. J. Control. Release 115 1 (2006) 85-93
106. Williams A.C., and Barry B.W. Penetration enhancers. Adv. Drug Deliv. Rev. 56 5 (2004) 603-618
107. Loftsson T., Somogyi G., and Bodor N. Effect of choline esters and oleic-acid on the penetration of acyclovir, estradiol, hydrocortisone, nitroglycerin, retinoic acid and trifluorothymidine across hairless mouse skin invitro. Acta Pharm. Nord. 1 5 (1989) 279-286
108. Hoelgaard A., Mollgaard B., and Baker E. Vehicle effect on topical drug delivery .4. Effect of n-methylpyrrolidone and polar lipids on percutaneous drug transport. Int. J. Pharm. 43 3 (1988) 233-240
109. Kaiho F., et al. Enhancing effect of cetyl lactate on the percutaneous-absorption of indomethacin in rats. Chem. Pharm. Bull. 37 4 (1989) 1114-1116
110. Sato K., Sugibayashi K., and Morimoto Y. Effect and mode of action of aliphatic esters on the invitro skin permeation of nicorandil. Int. J. Pharm. 43 1-2 (1988) 31-40
111. Rhee Y.S., et al. Effects of vehicles and enhancers on transdermal delivery of clebopride. Arch. Pharm. Res. 30 9 (2007) 1155-1161
112. Krishnaiah Y.S.R., et al. Penetration-enhancing effect of ethanolic solution of menthol on transdermal permeation of ondansetron hydrochloride across rat epidermis. Drug Deliv. 15 4 (2008) 227-234
113. Panchagnula R., et al. Transdermal delivery of naloxone: effect of water, propylene glycol, ethanol and their binary combinations on permeation through rat skin. Int. J. Pharm. 219 1-2 (2001) 95-105
114. Furuishi T., et al. Effect of permeation enhancers on the in vitro percutaneous absorption of pentazocine. Biol. Pharm. Bull. 30 7 (2007) 1350-1353
115. Funke A.P., et al. Transdermal delivery of highly lipophilic drugs: In vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations. Pharm. Res. 19 5 (2002) 661-668
116. Goldbergcettina M., et al. Enhanced transdermal delivery of estradiol in vitro using binary vehicles of isopropyl myristate and short chain alkanols. Int. J. Pharm. 114 2 (1995) 237-245
117. Lee C.K., et al. Skin permeation enhancement of Tegafur by ethanol panasate 800 or ethanol-water binary vehicle and combined effect of fatty-acids and fatty alcohols. J. Pharm. Sci. 82 11 (1993) 1155-1159
118. Lee P.J., et al. Evaluation of chemical enhancers in the transdermal delivery of lidocaine. Int. J. Pharm. 308 1-2 (2006) 33-39
119. Kakubari I., et al. Effects of solvents on skin permeation of formoterol fumarate. Biol. Pharm. Bull. 29 1 (2006) 146-149
120. Hansen E., et al. The effect of water on a new binary transdermal flux enhancer (Peg(3)-Me/IPP): An in vitro evaluation using estradiol. Drug Dev. Ind. Pharm. 23 1 (1997) 9-14
121. Fang L., et al. The enhancing effect of a triethanolamine-ethanol-isopropyl myristate mixed system on the skin permeation of acidic drugs. Biol. Pharm. Bull. 25 10 (2002) 1339-1344
122. Squillante E., et al. Optimization of in vitro nifedipine penetration enhancement through hairless mouse skin. Int. J. Pharm. 169 2 (1998) 143-154
123. Thomas N.S., and Panchagnula R. Combination strategies to enhance transdermal permeation of zidovudine (AZT). Pharmazie 58 12 (2003) 895-898
124. Fang C., et al. Synergistically enhanced transdermal permeation and topical analgesia of tetracaine gel containing menthol and ethanol in experimental and clinical studies. Eur. J. Pharm. Biopharm. 68 3 (2008) 735-740
125. Monti D., et al. Enhancement of transdermal penetration of dapiprazole through hairless mouse skin. J. Control. Release 33 1 (1995) 71-77
126. Agyralides G.G., Dallas P.P., and Rekkas D.M. Development and in vitro evaluation of furosemide transdermal formulations using experimental design techniques. Int. J. Pharm. 281 1-2 (2004) 35-43
127. Puglia C., et al. Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations. Int. J. Pharm. 228 1-2 (2001) 79-87
128. Karande P., and Mitragotri S. High throughput screening of transdermal formulations. Pharm. Res. 19 5 (2002) 655-660
129. Brodin A., et al. Phase-diagram and aqueous solubility of the lidocaine-prilocaine binary system. J. Pharm. Sci. 73 4 (1984) 481-484
130. Nyqvistmayer A.A., Brodin A.F., and Frank S.G. Phase distribution studies on an oil-water emulsion based on a eutectic mixture of lidocaine and prilocaine as the dispersed phase. J. Pharm. Sci. 74 11 (1985) 1192-1195
131. Calpena A.C., et al. A comparative in-vitro study of transdermal absorption of antiemetics. J. Pharm. Sci. 83 1 (1994) 29-33
132. Stott P.W., Williams A.C., and Barry B.W. Mechanistic study into the enhanced transdermal permeation of a model beta-blocker, propranolol, by fatty acids: a melting point depression effect. Int. J. Pharm. 219 1-2 (2001) 161-176
133. Stott P.W., Williams A.C., and Barry B.W. Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen. J. Control. Release 50 1-3 (1998) 297-308
134. Kang L.S., Jun H.W., and McCall J.W. Physicochemical studies of lidocaine-menthol binary systems for enhanced membrane transport. Int. J. Pharm. 206 1-2 (2000) 35-42
135. KaplunFrischoff Y., and Touitou E. Testosterone skin permeation enhancement by menthol through formation of eutectic with drug and interaction with skin lipids. J. Pharm. Sci. 86 12 (1997) 1394-1399
136. Coderch L., et al. Influence of cholesterol on liposome fluidity by EPR-relationship with percutaneous absorption. J. Control. Release 68 1 (2000) 85-95
137. Duplessis J., et al. Topical delivery of liposomally encapsulated gamma-interferon. Antiviral Res. 18 3-4 (1992) 259-265
138. van den Bergh B.A.I., et al. Elasticity of vesicles affects hairless mouse skin structure and permeability. J. Control. Release 62 3 (1999) 367-379
139. Egbaria K., Ramachandran C., and Weiner N. Topical application of liposomally entrapped ciclosporin evaluated by in vitro diffusion studies with human skin. Skin Pharmacol. 4 1 (1991) 21-28
140. Weiner N., et al. Liposomes-a novel topical delivery system for pharmaceutical and cosmetic applications. J. Drug Target. 2 5 (1994) 405-410
141. Fresta M., and Puglisi G. Application of liposomes as potential cutaneous drug delivery systems. In vitro and in vivo investigation with radioactively labelled vesicles. J. Drug Target. 4 2 (1996) 95-101
142. Fresta M., and Puglisi G. Corticosteroid dermal delivery with skin-lipid liposomes. J. Control. Release 44 2-3 (1997) 141-151
143. Yu H.Y., and Liao H.M. Triamcinolone permeation from different liposome formulations through rat skin in vitro. Int. J. Pharm. 127 1 (1996) 1-7
144. Liu H., et al. Topical delivery of different acyclovir palmitate liposome formulations through rat skin in vitro. Pharmazie 59 3 (2004) 203-206
145. Bouwstra J.A., and Honeywell-Nguyen P.L. Skin structure and mode of action of vesicles. Adv. Drug Deliv. Rev. 54 (2002) S41-S55
146. El Maghraby G.M.M., Williams A.C., and Barry B.W. Can drug-bearing liposomes penetrate intact skin?. J. Pharm. Pharmacol. 58 4 (2006) 415-429
147. Katahira N., et al. Enhancement of topical delivery of a lipophilic drug from charged multilamellar liposomes. J. Drug Target. 6 6 (1999) 405-414
148. Ogiso T., et al. Effect of positively and negatively charged liposomes on skin permeation of drugs. J. Drug Target. 9 1 (2001) 49
149. Manosroi A., Kongkaneramit L., and Manosroi J. Stability and transdermal absorption of topical amphotericin B liposome formulations. Int. J. Pharm. 270 1-2 (2004) 279-286
150. Choi M.J., and Maibach H.I. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol. Physiol. 18 5 (2005) 209-219
151. Sinico C., et al. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug penneation and vesicle-skin interaction. J. Control. Release 103 1 (2005) 123-136
152. Honeywell-Nguyen P.L., and Bouwstra J.A. Vesicles as a tool for transdermal and dermal delivery. Drug Discov. Today: Technol. 2 1 (2005) 67-74
153. Abraham W., and Downing D.T. Interaction between corneocytes and stratum corneum lipid liposomes in vitro. Biochim. Biophys. Acta 1021 2 (1990) 119-125
154. Hofland H.E.J., et al. Interactions of nonionic surfactant vesicles with cultured keratinocytes and human skin in vitro-a survey of toxicological aspects and ultrastructural changes in stratum corneum. J. Control. Release 16 1-2 (1991) 155-167
155. van den Bergh B.A.I., Salomons-de Vries I., and Bouwstra J.A. Interactions between liposomes and human stratum corneum studied by freeze-substitution electron microscopy. Int. J. Pharm. 167 1-2 (1998) 57-67
156. Zellmer S., Pfeil W., and Lasch J. Interaction of phosphatidylcholine liposomes with the human stratum corneum. Biochim. Biophys. Acta, Biomembr. 1237 2 (1995) 176-182
157. Cevc G., and Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim. Biophys. Acta 1104 1 (1992) 226-232
158. Cevc G., Schatzlein A., and Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim. Biophys. Acta, Biomembr. 1564 1 (2002) 21-30
159. Dayan N., and Touitou E. Carriers for skin delivery of trihexyphenidyl HCl: ethosomes vs. liposomes. Biomaterials 21 18 (2000) 1879-1885
160. Touitou E., et al. Ethosomes-novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J. Control. Release 65 3 (2000) 403-418
161. Mezei M., and Gulasekharam V. Liposomes-a selective drug delivery system for the topical route of administration .1. Lotion dosage form. Life Sci. 26 18 (1980) 1473-1477
162. Mezei M., and Gulasekharam V. Liposomes-a selective drug delivery system for the topical route of administration-gel dosage form. J. Pharm. Pharmacol. 34 7 (1982) 473-474
163. Touitou E., et al. Modulation of caffeine skin delivery by carrier design-liposomes versus permeation enhancers. Int. J. Pharm. 103 2 (1994) 131-136
164. Mezei M. Liposomes as a skin drug delivery system. In: Speiser D.D. (Ed). Topics in Pharmaceutical Sciences (1985), Elsevier, Amsterdam 345-358
165. Ferreira L.S., et al. In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis. Drug Dev. Ind. Pharm. 30 3 (2004) 289-296
166. Puglia C., et al. Evaluation of in-vivo topical anti-inflammatory activity of indometacin from liposomal vesicles. J. Pharm. Pharmacol. 56 10 (2004) 1225-1232
167. Ramon E., et al. Liposomes as alternative vehicles for sun filter formulations. Drug Deliv. 12 2 (2005) 83-88
168. Kitagawa S., and Kasamaki M. Enhanced delivery of retinoic acid to skin by cationic liposomes. Chem. Pharm. Bull. 54 2 (2006) 242-244
169. Elsayed M.M.A., et al. Lipid vesicles for skin delivery of drugs: Reviewing three decades of research. Int. J. Pharm. 332 1-2 (2007) 1-16
170. Mezei M. Biodisposition of liposome-encapsulated active ingredients applied on the skin. In: Falco O.B., Korting H.C., and Maibach H.I. (Eds). Liposome Dermatics (1992), Springer-Verlag, Berlin 206-214
171. Schreier H., and Bouwstra J. Liposomes and niosomes as topical drug carriers-dermal and transdermal drug delivery. J. Control. Release 30 1 (1994) 1-15
172. Uchegbu I.F., and Florence A.T. Nonionic surfactant vesicles (niosomes)-physical and pharmaceutical chemistry. Adv. Colloid Interface Sci. 58 1 (1995) 1-55
173. Uchegbu I.F., and Vyas S.P. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int. J. Pharm. 172 1-2 (1998) 33-70
174. Reddy D.N., and Udupa N. Formulation and evaluation of oral and transdermal preparations of flurbiprofen and piroxicam incorporated with different carriers. Drug Dev. Ind. Pharm. 19 7 (1993) 843-852
175. VanHal D., et al. Diffusion of estradiol from non-ionic surfactant vesicles through human stratum corneum in vitro. STP Pharm. Sci. 6 1 (1996) 72-78
176. Paolino D., et al. In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery. Biomed. Microdevices 9 4 (2007) 421-433
177. Azeem A., et al. Nonionic surfactant vesicles as a carrier for transdermal delivery of frusemide. J. Dispers. Sci. Technol. 29 5 (2008) 723-730
178. Touitou E., Godin B., and Weiss C. Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug Dev. Res. 50 3-4 (2000) 406-415
179. Touitou E., and Godin B. Ethosomes for skin delivery. J. Drug Deliv. Sci. Technol. 17 5 (2007) 303-308
180. Rao Y.F., et al. In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers. AAPS Pharmscitech 9 3 (2008) 860-865
181. Dubey V., et al. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J. Control. Release 123 2 (2007) 148-154
182. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 13 3-4 (1996) 257-388
183. Cevc G., et al. The skin: A pathway for systemic treatment with patches and lipid-based agent carriers. Adv. Drug Deliv. Rev. 18 3 (1996) 349-378
184. Honeywell-Nguyen P.L., Groenink H.W.W., and Bouwstra J.A. Elastic vesicles as a tool for dermal and transdermal delivery. J. Liposome Res. 16 3 (2006) 273-280
185. Cevc G., et al. Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim. Biophys. Acta, Biomembr. 1368 2 (1998) 201-215
186. El Maghraby G.M.M., Williams A.C., and Barry B.W. Skin delivery of oestradiol from deformable and traditional liposomes: mechanistic studies. J. Pharm. Pharmacol. 51 10 (1999) 1123-1134
187. El Maghraby G.M.M., Williams A.C., and Barry B.W. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int. J. Pharm. 196 1 (2000) 63-74
188. El Maghraby G.M.M., Williams A.C., and Barry B.W. Skin delivery of oestradiol from lipid vesicles: importance of liposome structure. Int. J. Pharm. 204 1-2 (2000) 159-169
189. Trotta M., et al. Deformable liposomes for dermal administration of methotrexate. Int. J. Pharm. 270 1-2 (2004) 119-125
190. Oh Y.K., et al. Skin permeation of retinal in Tween 20-based deformable liposomes: in-vitro evaluation in human skin and keratinocyte models. J. Pharm. Pharmacol. 58 2 (2006) 161-166
191. Jain S., et al. Transfersomes-a novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. Drug Dev. Ind. Pharm. 29 9 (2003) 1013-1026
192. Lee E.H., et al. Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes. Biomaterials 26 2 (2005) 205-210
193. Elsayed M.M.A., et al. Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen. Pharmazie 62 2 (2007) 133-137
194. El Maghraby G.M.M., Williams A.C., and Barry B.W. Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro. J. Pharm. Pharmacol. 53 8 (2001) 1069-1077
195. Planas M.E., et al. Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes. Anesth. Analg. 75 4 (1992) 615-621
196. Guo J.X., et al. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int. J. Pharm. 194 2 (2000) 201-207
197. Cevc G. Transidermal drug delivery of insulin with ultradeformable carriers. Clin. Pharmacokinet. 42 5 (2003) 461-474
198. Cevc G., and Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochim. Biophys. Acta, Biomembr. 1514 2 (2001) 191-205
199. Cevc G., and Blume G. Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes (R). Biochim. Biophys. Acta, Biomembr. 1614 2 (2003) 156-164
200. Fesq H., et al. Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome (R) in comparison with equipotent cream and ointment: a randomized controlled trial. Br. J. Dermatol. 149 3 (2003) 611-619
201. Cevc G., and Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim. Biophys. Acta, Biomembr. 1663 1-2 (2004) 61-73
202. Jain S., et al. Proultraflexible lipid vesicles for effective transdermal delivery of levonorgestrel: development, characterization, and performance evaluation. AAPS Pharmscitech 6 3 (2005)
203. Garg M., et al. Ethinylestradiol-loaded ultraflexible liposomes: pharmacokinetics and pharmacodynamics. J. Pharm. Pharmacol. 58 4 (2006) 459-468
204. Song Y.K., and Kim C.K. Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes. Biomaterials 27 2 (2006) 271-280
205. Trotta M., et al. Elastic liposomes for skin delivery of dipotassium glycyrrhizinate. Int. J. Pharm. 241 2 (2002) 319-327
206. Jain S., Tiwary A.K., and Jain N.K. Sustained and targeted delivery of an anti-HIV agent using elastic liposomal formulation: mechanism of action. Curr. Drug Deliv. 3 (2006) 157-166
207. Kogan A., and Garti N. Microemulsions as transdermal drug delivery vehicles. Adv. Colloid Interface Sci. 123 (2006) 369-385
208. Karasulu H.Y. Microemulsions as novel drug carriers: the formation, stability, applications and toxicity. Expert Opin. Drug Deliv. 5 1 (2008) 119-135
209. Santos P., et al. Application of microemulsions in dermal and transdermal drug delivery. Skin Pharmacol. Physiol. 21 5 (2008) 246-259
210. Date A.A., and Patravale V.R. Microemulsions: applications in transdermal and dermal delivery. Crit. Rev. Ther. Drug Carrier Syst. 24 6 (2007) 547-596
211. Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Adv. Drug Deliv. Rev. 54 (2002) S77-S98
212. Gupta R.R., Jain S.K., and Varshney M. AOT water-in-oil microemulsions as a penetration enhancer in transdermal drug delivery of 5-fluorouracil. Colloids Surf. B, Biointerfaces 41 1 (2005) 25-32
213. Changez M., et al. Effect of the composition of lecithin/n-propanol/isopropyl myristate/water microemulsions on barrier properties of mice skin for transdermal permeation of tetracaine hydrochloride: In vitro. Colloids Surf. B, Biointerfaces 50 1 (2006) 18-25
214. Gallarate M., et al. On the stability of ascorbic acid in emulsified systems for topical and cosmetic use. Int. J. Pharm. 188 2 (1999) 233-241
215. Zhu W.W., et al. Formulation design of microemulsion for dermal delivery of penciclovir. Int. J. Pharm. 360 1-2 (2008) 184-190
216. Glomot F., et al. Improvement in availability and stability of a dermocorticoid by inclusion in beta-cyclodextrin. Int. J. Pharm. 46 1-2 (1988) 49-55
217. Adachi H., et al. Combination effects of o-carboxymethyl-o-ethyl-beta-cyclodextrin and penetration enhancer hpe-101 on transdermal delivery of prostaglandin-E(1) in hairless mice. Eur. J. Pharm. Sci. 1 3 (1993) 117-123
218. Martini A., et al. Critical micellar concentration shifting as a simple tool for evaluating cyclodextrin/enhancer interactions. Int. J. Pharm. 127 2 (1996) 239-244
219. Legendre J.Y., et al. Effects of beta-cyclodextrins on skin: implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977. Eur. J. Pharm. Sci. 3 6 (1995) 311-322
220. Loftsson T., et al. Cyclodextrins as co-enhancers in dermal and transdermal drug delivery. Pharmazie 53 2 (1998) 137-139
221. Nokhodchi A., et al. The enhancement effect of surfactants on the penetration of lorazepam through rat skin. Int. J. Pharm. 250 2 (2003) 359-369
222. Xu D.H., et al. Synergistic effects of ethosomes and chemical enhancers on enhancement of naloxone permeation through human skin. Pharmazie 62 4 (2007) 316-318
223. Hoch M. Calculation of ternary, quaternary, and higher-order phase diagrams from binary diagrams and binary thermodynamic data. J. Phase Equilib. 14 (1993) 710-717
224. Luongo-Ortiz J.F., and Starling K.E. A new combining rule for mixture equations of state: higher order composition dependencies reduce to quadratic composition dependence. Fluid Phase Equilib. 132 1-2 (1997) 159-167
225. Lee S.C., and Woo E.M. Binary versus ternary interactions in a completely miscible three-polymer blend system: poly (epsilon-caprolactone) with two different methacrylic polymers. J. Polym. Sci., Part B, Polym. Phys. 40 (2002) 747-754